Figure 4. Cumulative incidence of dasatinib discontinuation. Deaths or relapses were considered as competing risks for dasatinib discontinuation.
Figure 4

Cumulative incidence of dasatinib discontinuation. Deaths or relapses were considered as competing risks for dasatinib discontinuation.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal